SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on September 28, 2021. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding a new strategic partnership. The registrant is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial performance data.
Material Changes and Corporate Events
- New Agreement: On September 28, 2021, the Company entered into a manufacturing and professional services agreement with Plexus Corp.
- Disclosure Method: The details of this agreement were announced via a press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors related to the new agreement. The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific terms, duration, and financial implications of the agreement with Plexus Corp.
- Verify the operational impact of the manufacturing and professional services agreement on future production capacity.
- Confirm if this agreement alters the Company's existing supply chain strategy or cost structure.
- Note that the filing explicitly disclaims an obligation to provide future updates on this specific disclosure.